Empower Clinics - Director, Alexis Wukich.
Director, Alexis Wukich.
Source: LinkedIn.
  • Empower Clinics (EPW) announced the appointment of Alexis Wukich to its Board of Directors, effective immediately
  • Wukich has fifteen years of experience as an entrepreneur, lawyer, and talent management leader in the U.S. medical industry
  • Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics
  • Empower Clinics Inc. (EPW) is down 7.14 per cent trading at $0.065 per share

Empower Clinics (EPW) has appointed Alexis Wukich to its Board of Directors.

Wukich has fifteen years of experience as an entrepreneur, lawyer, and talent management leader in the U.S. medical industry. She served as Executive Vice President and Corporate Counsel of Danan Healthcare Consulting Group. She was also Managing Director of Arriba International Staffing Service, a healthcare staffing company that specializes in the recruitment, sponsorship, and placement of international healthcare staff.

Wukich has a Master of Business Administration from University of Pittsburgh’s Katz Graduate School of Business and a JD Law from University of Pittsburgh School of Law.

Steven McAuley, Chairman and CEO of Empower Clinics, commented on the appointment,

“We are so pleased that Alexis has chosen to join our Board. She brings a clear understanding of the challenges faced by Americans when seeking healthcare solutions. The combination of her unique operations, legal and government relations experience in U.S. healthcare is invaluable as we focus and advance our growth in the U.S. market.”

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics.

Empower Clinics Inc. (EPW) is down 7.14 per cent, trading at $0.065 per share at 2:11 pm ET.


More From The Market Online
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.